MELPERONE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H22FNO
Molecular Weight	263.3504
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1

InChI

InChIKey=DKMFBWQBDIGMHM-UHFFFAOYSA-N

InChI=1S/C16H22FNO/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14/h4-7,13H,2-3,8-12H2,1H3

HIDE SMILES / InChI

Molecular Formula	C16H22FNO
Molecular Weight	263.3504
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ratiopharm.de/index.php?eID=dumpFile&t=f&f=60721&g=-1&r=1894%2C1894&token=c00130080812868362409a3ab52b4a122b2af3ad

Melperone is an antipsychotic drug which is used in Europe for the treatment of sleep disorders, agitation and confusion states. The exact mechanism of melperone action is unknown.

CNS Activity

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Sleep disorder 25 Sources: http://www.ratiopharm.de/index.php?eID=dumpFile&t=f&f=60721&g=-1&r=1894%2C1894&token=c00130080812868362409a3ab52b4a122b2af3ad	Primary	Approved 8583	MELPERON Approved Use Melperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients.
Confusional state 2 Sources: http://www.ratiopharm.de/index.php?eID=dumpFile&t=f&f=60721&g=-1&r=1894%2C1894&token=c00130080812868362409a3ab52b4a122b2af3ad	Primary	Approved 8583	MELPERON Approved Use Melperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients.
Psychomotor agitation 6 Sources: http://www.ratiopharm.de/index.php?eID=dumpFile&t=f&f=60721&g=-1&r=1894%2C1894&token=c00130080812868362409a3ab52b4a122b2af3ad	Primary	Approved 8583	MELPERON Approved Use Melperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients.

C_max

Value	Dose	Analyte	Population
43 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
100 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
340 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
206 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
218 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
478 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1490 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
211 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
523 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
570 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/	50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	MELPERONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2479227/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2479227/	Other AEs: extrapyramidal side effects... Other AEs: extrapyramidal side effects (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/2479227/
100 mg 4 times / day multiple, oral Highest studied dose Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12765745/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12765745/	Sources: https://pubmed.ncbi.nlm.nih.gov/12765745/

AEs

AE	Significance	Dose	Population
extrapyramidal side effects	4 patients	100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2479227/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2479227/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP3 246 MRP4 290 MRP2 499 BSEP 550 CYP1A2 2153 CYP2C19 2057 CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MzExMzQifX0=	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MzExMzQifX0=	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MzExMzQifX0=	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MzExMzQifX0=	no [IC50 >133 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 50.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 108.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 101.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 97.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 98.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results	yes [IC50 0.195 uM]	yes (co-administration study) Comment: Melperone decreased dose-adjusted serum venlafaxine concentration by 71.7%. Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 6.0	yes [IC50 34.6713 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 94 \| 95	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/15387#section=Biological-Test-Results Page: 4.0

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.	2010-10	20441727
Four-digit replantation in a mentally retarded person: a case report.	2010-09-30	20976275
Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.	2010-04-30	20199813
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.	2010-02	19864614
Acute administration of clozapine and risperidone altered dopamine metabolism more in rat caudate than in nucleus accumbens: a dose-response relationship.	2009-08-20	21179339
Antipsychotics and risk of venous thromboembolism: A population-based case-control study.	2009-08-09	20865083
Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics.	2009-07	19551763
Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.	2009-04	18989659
The ABCB1 transporter gene and antidepressant response.	2009-03-24	20948663
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).	2008-12-22	19102734
[Recurrent dysregulation of body temperature during antipsychotic pharmacotherapy].	2008-03	17902059
Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.	2006-04	16534635
Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.	2006-03-30	16573831
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.	2006-02-28	16507108
Antipsychotic drugs and QT prolongation.	2005-09	16096514
Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.	2005-02	15694653
P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6.	2004-12	15582917
[The case of a 86-years old woman first diagnosed with Huntington's disease].	2004-11	15570530
A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.	2003-07-01	12765745
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.	2003-03	12644990
The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.	2003-01-01	12413636
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.	2003-01	12649767
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.	2002-11-29	12445705
Melperone in the treatment of neuroleptic-resistant schizophrenia.	2001-12-31	11814539
[Pharmacotherapeutical approaches to insomnia patients with cardiac diseases and after heart transplantation].	2001-10	11757467
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.	2001-10	11561066
Clinical management of agitation in the elderly with tiapride.	2001-01	11520478
New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.	1999-06	10435384
Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents.	1989-06	2726785

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of melperone (in form of hydrochloride salt) is 25-75 mg/day. In the case of restless and confused patients the drug is given at a dose of 50-100 mg at the beginning of the treatment. The dose can be increased up to 200 mg if necessary. In severe disorders of confusion and confusion with aggression and hallucinatory conditions, the daily dose can be increased to up to 400 mg melperone HCl.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:15 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:15 GMT 2025`
Record UNII	J8WA3K39B7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUNIL

Preferred Name

English

MELPERONE

Official Name

English

METYLPERON

Common Name

English

MELPERONE [MI]

Common Name

English

Melperone [WHO-DD]

Common Name

English

melperone [INN]

Common Name

English

FG 5111

Code

English

FG-5111

Code

English

4'-FLUORO-4-(4-METHYLPIPERIDINO)BUTYROPHENONE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710